Genomenon
Ann Arbor, US · Founded 2014 · Delaware corporation · 139 employees on LinkedIn · 8 known investors
Find your way into Genomenon
350 people in our graph share verified history with the Genomenon team — schools, employers, funds. One of them is your warm intro.
Hyun Koounlockedknows Eli Salembier · together at University of Michigan - Stephen M. Ross School of Business (overlapped)
×2knows the team · via University of Michigan - Stephen M. Ross School of Business
×5knows the team · via Wesleyan University
knows the team · via Riverdale Country School
×3knows the team · via Joan & Sanford I. Weill Medical College of Cornell University
Genomenon uses AI to read biomedical literature and expert scientists to curate variant- and patient-level genomic evidence, delivering regulatory-grade real-world evidence. Its products, including Mastermind and CKB, serve drug development teams and clinical genetic testing labs for variant interpretation and drug program decisions.
Founders & leadership
Genomenon was founded in 2014 by Mark Kiel.
ES
Eli SalembierinCFO and Director2015–2017Eli Salembier has spent over fifteen years in finance and accounting roles in complex, fast-paced organizations, with expertise in business modeling, financial planning and analysis, and ERP systems administration.
SG
Sam GlobusinChief Operating OfficerChief Operating Officer at Genomenon, Sam Globus previously spent nearly six years at Celmatix as an operations leader, where he scaled the organization and oversaw the development and regulatory approval of a genetic test for infertility markers. He holds a PhD in Biochemistry, Cell, and Molecular Biology from Weill Cornell and has degrees from Oxford and Columbia, with research experience at Memorial Sloan-Kettering.
DG
BG
Brian GroarkinChief Financial Officer
Board
PG
Patricia GlazaBoard director
MG
SS
Sonya SepahbanBoard director
Investors · 8
Reported raises · per SEC filings
Form D private placements$34.8M disclosed across 5 rounds · 2015–2026
▶$6MraisedJul 2026 · 30 investors · BiotechnologyRule 506(b)
▶$6MraisedJul 2026 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael KleinExecutive Officer, Director
- Mark KielExecutive Officer, Director
- Patricia GlazaDirector
- David GregorkaDirector
- Michael GrossDirector
- Brian GroarkExecutive Officer
- Sam GlobusExecutive Officer
- Offering amount
- $10M
- Amount sold
- $6M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedMay 2024 · 30 investors · BiotechnologyRule 506(b)
▶$5.5MraisedMay 2024 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark KielExecutive Officer, Director
- Patricia GlazaDirector
- Michael KleinExecutive Officer, Director
- David GregorkaDirector
- Michael GrossDirector
- Sam GlobusExecutive Officer
- Sean KearneyExecutive Officer
- Offering amount
- $6M
- Amount sold
- $5.5M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedMar 2022 · 23 investors · BiotechnologyRule 506(b)
▶$20MraisedMar 2022 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael KleinExecutive Officer, Director
- David GregorkaDirector
- Patricia GlazaDirector
- Michael GrossDirector
- Mark KielExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedMay 2020 · 36 investors · BiotechnologyRule 506(b)
▶$2.9MraisedMay 2020 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark KielExecutive Officer, Director
- Michael KleinExecutive Officer, Director
- David GregorkaDirector
- Steve SchwartzExecutive Officer
- Patricia GlazaDirector
- Charles MoretDirector
- Offering amount
- $3M
- Amount sold
- $2.9M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$446KraisedAug 2015 · 11 investors · ComputersRule 506(b)
▶$446KraisedAug 2015 · 11 investors · Computers
Rule 506(b)Officers, directors & promoters on the filing
- Eli SalembierExecutive Officer, Director
- Mark KielExecutive Officer, Director
- Sonya SepahbanDirector
- Offering amount
- $1M
- Amount sold
- $446K
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Genomenon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Genomenon do?
- Genomenon uses AI to read biomedical literature and expert scientists to curate variant- and patient-level genomic evidence, delivering regulatory-grade real-world evidence. Its products, including Mastermind and CKB, serve drug development teams and clinical genetic testing labs for variant interpretation and drug program decisions.
- Who founded Genomenon?
- Genomenon was founded by Mark Kiel in 2014.
- Who are Genomenon's investors?
- Genomenon's investors include Beringea, Green Park & Golf Ventures, ID Ventures, Invest Michigan, IrishAngels, Marram Ventures, Michigan Rise, Spring Mountain Capital.
- How much funding has Genomenon raised?
- Genomenon has disclosed $34.8M raised across 5 rounds.
- Where is Genomenon headquartered?
- Genomenon is headquartered in Ann Arbor, US.